Company Profile
Profil emiten IDX — keuangan, direksi, komisaris, anak usaha
PT Prodia Widyahusada Tbk.
PRDA
Sector: Healthcare
Industry: Healthcare Providers
Sub Sector: Healthcare Equipment & Providers
Sub Industry: Healthcare Providers
PRDA
09:01
2.470
▲ +40 (+1.65%)
High 0
Low 0
Open —
Prev 2.430
TVol 52.800
Highlight Keuangan (2026 Q2) (In Rp)
EPS
165
ROE
6,63%
ROA
5,87%
Book Value
2.495
Net Income
77,54 M
Total Sales
1,11 T
Total Assets
2,64 T
DER
0.13x
Struktur Pemegang Saham (>1%)
Free Float Information
Saham tersebar di publik
12,11%
PT. PRODIA UTAMA 🔗
57,00%
Corporate · Lokal
BIO MAJESTY PTE LTD 🔗
12,00%
Corporate · Asing
PRODIA WIDYAHUSADA TBK. 🔗
5,09%
Corporate · Lokal
REKSA DANA SYARIAH HENAN EKUITAS SYARIAH BERKAH 🔗
4,94%
Mutual Funds · Lokal
EFG BANK AG, SINGAPORE BRANCH A/C CLIENTS 🔗
2,69%
Private Bank · Asing
SWEDBANK ROBUR SMALL CAP EMERGING MARKETS 🔗
2,03%
Mutual Funds · Asing
REKSA DANA HPAM SYARIAH EKUITAS 🔗
1,99%
Mutual Funds · Lokal
CACEIS BANK, LUXEMBOURG BRANCH/ UCITS CLIENTS 🔗
1,11%
Bank · Asing
BANQUE PICTET AND CIE SA ARJUNA FUND PTE. LTD 🔗
1,04%
Hedge Fund · Asing
Tentang Perusahaan
PT Prodia Widyahusada Tbk (the Company) was established based on the Deed of Notary Sri Rahayu, SH, No. 14 dated February 8, 1988. Clinical Laboratory Prodia was first established in Solo, Central Java, on May 7, 1973 by a few idealists pharmaceutical educational background.
Produk & Lini Bisnis
Currently, the Company's principal activity is to provide health check up.
Dewan Direksi
DD
Dr. Dewi Muliaty, M.Si
President Director
LK
Liana Kuswandi, SE,M.Fin
Director
AH
Andri Hidayat, M.Si
Director
DI
Dr. Indriyanti Rafi Sukmawati, M.Si
Director
IZ
Ida Zuraida
Director
Dewan Komisaris
DA
Drs. Andi Widjaja, MBA
President Commissioner
DG
Drs. Gunawan Prawiro Soeharto
Commissioner
DE
Dra. Endang Wahjuningtyas Hoyaranda
Commissioner
JF
Joseph Fellipus Peter Luhukay
Independent Commissioner
KL
Keri Lestari Dandan
Independent Commissioner
Anak Usaha & Afiliasi
NamaDomisili%
PT Prodia OHI International
Health services
 Jakarta 40.00%
PT Prodia Stemcell Indonesia
Health support services
 Jakarta 95.00%
PT Prodia Diagnostic Line
Trade and industry
 Cikarang 80.00%
PT Innovasi Diagnostika
Health services
 Jakarta 52.00%
Trend Keuangan (5 periode terakhir) — hover bar untuk detail
Total Sales Net Income (+) Net Income (-)
2,3M 1,7M 1,1M 570jt 0 Sales 2025Q2: Rp 1.027.349.000 Net Income 2025Q2: Rp 69.641.000 2025Q2 Sales 2025Q3: Rp 1.580.555.000 Net Income 2025Q3: Rp 114.560.000 2025Q3 Sales 2025Q4: Rp 2.281.704.000 Net Income 2025Q4: Rp 206.788.000 2025Q4 Sales 2026Q1: Rp 501.383.000 Net Income 2026Q1: Rp 17.229.000 2026Q1 Sales 2026Q2: Rp 1.114.676.000 Net Income 2026Q2: Rp 77.544.000 2026Q2
2025 Q2
EPS 149
ROE 6,02%
2025 Q3
EPS 163
ROE 6,61%
2025 Q4
EPS 221
ROE 8,65%
2026 Q1
EPS 74
ROE 2,86%
2026 Q2
EPS 165
ROE 6,63%
Laporan Keuangan Historis (5 Periode Terakhir) (In Rp)
PeriodeTotal SalesNet IncomeTotal AssetsTotal EquityEPSROEDER
2026 Q2 1,11 T 77,54 M 2,64 T 2,34 T 165 6,63% 0.13x
2026 Q1 501,38 M 17,23 M 2,68 T 2,41 T 74 2,86% 0.11x
2025 Q4 2,28 T 206,79 M 2,70 T 2,39 T 221 8,65% 0.13x
2025 Q3 1,58 T 114,56 M 2,58 T 2,31 T 163 6,61% 0.12x
2025 Q2 1,03 T 69,64 M 2,57 T 2,31 T 149 6,02% 0.11x
History Harga Penutupan & Book Value
TahunQrtClose Price (Rp)Book Value (Rp)ROA
2026 2 2.400 2.495 5,87%
2026 1 2.700 2.570 2,58%
2025 4 2.300 2.551 7,67%
2025 3 2.650 2.465 5,92%
2025 2 2.730 2.467 5,41%
Data diperbarui pada: 2026-05-12 11:40:00